 |
| |
| |
 |
| Accelerated Holding Corp. |
OBP IV |
New York, NY
Accelerated Holding creates and efficiently develops new enterprises within the medical technology arena, focusing on the cardiovascular market, by leveraging its infrastructure and the know-how of involved clinicians and researchers.
|
|
 |
| |
 |
| Affinium Pharmaceuticals, Ltd. |
OBP V |
Toronto, Ontario, Canada
www.afnm.com
Affinium is a pharmaceutical company focused on the clinical development of antibacterials. Their lead development program encompasses a potent, orally available, novel antibiotic class for the treatment of antibiotic resistant staphylococcal infections.
|
|
|
| |
 |
| Astex Therapeutics Ltd. |
OBP II, III |
Cambridge, UK
www.astex-therapeutics.com
Astex is a drug discovery company applying novel protein structure-based technologies for the discovery of small molecule therapeutics.
|
|
|
| |
 |
| BrainCells Inc. |
OBP IV |
La Jolla, CA
www.braincellsinc.com
BrainCells Inc. is a neurogenesis-based drug discovery and development company targeting novel therapies for disorders of mood and anxiety.
|
|
|
| |
 |
| Cambrios Technologies Corp. |
OBP IV |
Sunnyvale, CA
www.cambrios.com
Cambrios Technologies Corp. applies peptide affinity and biological patterning technologies to commercially important materials in semiconductor and other industries. Cambrios’ technologies enable rapid and low cost formation of patterned thin films of essentially any material, and are of particular use in large area electronic applications such as flat panel displays.
|
|
|
| |
 |
| Ceres, Inc. |
OBP II |
Thousand Oaks, CA
www.ceres.net
Ceres is a plant genomics company identifying key genes determining seed size, quantity, and yield amounts, as well as pesticide and herbicide resistance.
|
|
|
| |
 |
| CircuLite, Inc. |
OBP IV |
Saddle Brook, NJ and Aachen, Germany
www.circulite.net
CircuLite develops superficially implanted ventricular assist devices to treat congestive heart failure that align with the operating skills of the interventional cardiologist.
|
|
|
| |
 |
| Coherex Medical, Inc. |
OBP V |
www.coherex.com
Salt Lake City, UT
Coherex Medical is developing safer technologies such as a minimally invasive implant to close a heart defect called a patent foramen ovale, or PFO, and to induce tissue growth. PFO has been linked to at least two medical conditions that may benefit greatly from closure: cryptogenic stroke and migraine.
|
|
|
| |
 |
| Concentric Medical, Inc. |
OBP IV |
Mountain View, CA
www.concentric-medical.com
Concentric Medical is building a franchise in neurovascular intervention by developing new device-based
treatments for ischemic and hemorrhagic stroke. Concentric’s leading product, the proprietary MERCI™ System
has the potential of revolutionizing ischemic stroke intervention by providing a simple and innovative
mechanical method of removing thrombus to restore blood flow.
|
|
|
| |
 |
| Dicerna Pharmaceuticals, Inc. |
OBP V |
Cambridge, MA
www.dicerna.com
Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.
|
|
|
| |
 |
| Enanta Pharmaceuticals, Inc. |
OBP III |
Watertown, MA
www.enanta.com
Enanta Pharmaceuticals is using its cutting-edge chemistry technology and drug
discovery capabilities to create best in class small molecule drugs. The company is initially
focused on building a pipeline of first generation bridged bicyclic macrolide and ketolide
antibiotics to combat bacterial resistance in the treatment of respiratory tract infections (RTI)
and hospital borne diseases.
|
|
|
| |
 |
| Ensemble Therapeutics Corporation |
OBP IV |
Cambridge, MA
www.ensembletx.com
Utilizes its novel DNA Programmed Chemistry to direct synthetic organic chemical reactions in order to overcome the limitations - such as speed, expense and structural diversity - of methods currently used to generate novel small molecules.
|
|
|
| |
 |
| eSionic |
OBP IV |
Menlo Park, CA
www.esionic.com
Proprietary molecular systems for the energy storage market.
|
|
|
| |
 |
| Glori Energy |
OBP V |
Houston, TX
www.glorienergy.com
Glori Energy is innovating for the next generation by servicing the upstream oil industry with breakthrough biotechnology that safely increases oil production.
|
|
|
| |
 |
| IntraPace, Inc. |
OBP IV |
Menlo Park, Ca
www.intrapace.com
IntraPace is developing an endoscopically delivered gastric pacemaker for obesity treatment.
|
|
|
| |
|
| Laboratory Partners, Inc. |
OBP IV |
Palo Alto, CA
Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.
|
|
|
| |
 |
| Luca Technologies |
OBP V |
Golden, CO
www.lucatechnologies.com
Luca Technologies is developing a novel, long-term, biotechnology-driven solution to rising U.S. dependence on foreign energy sources.
|
|
|
| |
 |
| Mitralign, Inc. |
OBP IV |
Tewksbury, MA
www.mitralign.com
Develops a novel percutaneous transcatheter medical device for the treatment of mitral valve regurgitation, a disorder than can either cause or be exacerbated by congestive heart failure.
|
|
|
| |
 |
| nFocus Neuromedical, Inc. |
OBP V |
Menlo Park, CA
www.nfocusneuro.com
nFocus develops innovative next generation neurovascular devices for the treatment of wide neck aneurysms and large arterio-venous malformations (AVMs).
|
|
|
| |
 |
| Radius |
OBP IV |
Cambridge, MA
www.radiuspharm.com
Radius is a privately held company that is a leader in the discovery and development of a new generation of drug therapies for osteoporosis and women’s health.
|
|
|
| |
 |
| Rib-X Pharmaceuticals, Inc. |
OBP IV |
New Haven, CT
www.rib-x.com
Rib-X uses structure-based drug design to discover new
classes of antibiotics based on the high-resolution crystal structure of the 50s ribosomal subunit.
|
|
|
| |
 |
| SmartPill Corporation |
OBP V |
Buffalo, NY
www.smartpillcorp.com
The SmartPill Corporation is a developer and manufacturer of ingestible, capsule-based medical devices that aid in the diagnosis, definition and therapeutic intervention of gastrointestinal disorders and diseases. Their flagship product, the SmartPill pH.p., is an ingestible capsule that measures acidity, pressure and temperature within the entire GI tract to diagnose GI motility disorders. This ‘pill’ is currently FDA approved to diagnose certain GI conditions.
|
|
|
| |
 |
| superDimension, Ltd. |
OBP IV |
Herzliya, Israel and Plymouth, MN
www.superdimension.com
superDimension has a minimally invasive technology platform for interventional pulmonology, providing clinicians with 3-D visualization. This enables physicians to direct a variety of instruments through the lungs.
|
|
|
| |
 |
| Tragara Pharmaceuticals, Inc. |
OBP V |
San Diego, CA
www.tragarapharma.com
Tragara Pharmaceuticals, Inc. is a clinical-stage oncology specialty pharmaceuticals company focusing on the development of therapeutics in cancer and inflammation related disorders.
|
|
|
| |
 |
| VaxInnate Corporation |
OBP IV |
Cranbury, NJ and New Haven, CT
www.vaxinnate.com
VaxInnate is developing prophylactic and therapeutic vaccines; technology based on research and discoveries of leading scientists from Yale University.
|
|
|
| |
 |
| Xencor, Inc. |
OBP V |
Monrovia, CA
www.xencor.com
Xencor is a later-stage company that has successfully developed a protein engineering technology and has used that technology to develop a clinical pipeline. Xencor has partnered with leading biotech companies, including Genentech and Eli Lilly and is designing next-generation protein drug candidates with improved selectivity, efficacy and safety.
|
|
|
| |